ZD4054 demonstrates improved overall survival in prostate cancer

Dreicer, Robert
March 2008
Hem/Onc Today;3/10/2008, Vol. 9 Issue 4, p38
The article discusses research on the efficacy of ZD4054 in prostate cancer presented during the 2008 Genitourinary Cancers Symposium in San Francisco, California from February 14 to 16, 2008. According to the study by Dr. Nancy Dawson and colleagues at the Prostace Center of Lombardi Comprehensive Cancer Center at Georgetown University, survival in patients with metastatic hormone-resistant prostate cancer given the investigational endothelin receptor antagonist from AstraZeneca improved. The study involved 312 patients.


Related Articles

  • Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer. Olapade-Olaopa, E O; Moscatello, D K; MacKay, E H; Horsburgh, T; Sandhu, D P S; Terry, T R; Wong, A J; Habib, F K // British Journal of Cancer;1/1/2000, Vol. 82 Issue 1, p186 

    Earlier studies have demonstrated an unexplained depletion of the epidermal growth factor receptor (EGFR) protein expression in prostatic cancer. We now attribute this phenomenon to the presence of a variant EGFR (EGFRvIII) that is highly expressed in malignant prostatic neoplasms. In a...

  • The role of IL-6 in the radiation response of prostate cancer. Chun-Te Wu; Miao-Fen Chen; Wen-Cheng Chen; Ching-Chuan Hsieh // Radiation Oncology;2013, Vol. 8 Issue 1, p1 

    Background: Hormone-resistant (HR) prostate cancers are highly aggressive and respond poorly to treatment. IL-6/STAT3 signaling has been identified to link with the transition of HR and aggressive tumor behavior. The role of IL-6 in the radiation response of prostate cancer was investigated in...

  • European Conference of Clinical Oncology.  // BioWorld Today;9/26/2007, Vol. 18 Issue 187, p3 

    The article reveals the results of the Phase II Endothelin A Proof of Concept study of ZD4054 by AstraZeneca plc. The study showed no differences in progression-free survival in hormone-resistant prostate cancer, but show survival data. ZD4054 is a specific endothelin A receptor antagonist. A...

  • Role of DNA methyltransferase 1 in hormone-resistant prostate cancer. Miao-Fen Chen; Wen-Cheng Chen; Yu-Jia Chang; Ching-Fang Wu; Chun-Te Wu // Journal of Molecular Medicine;Sep2010, Vol. 88 Issue 9, p953 

    Given the poor outcome of patients with hormone-resistant (HR) prostate cancer, new strategies are needed to improve the current therapeutic regimens and/or develop novel treatments. We therefore aimed to provide a better understanding of the molecular mechanisms involved in the aggressive tumor...

  • What's hot in the prostate? Gleave, M.; Evans, C. P. // Prostate Cancer & Prostatic Diseases;2004, Vol. 7 Issue 1, p2 

    Presents abstracts of several studies on prostate cancer. "MTOPS: Combination Therapy for BPH," by McConnell et al; "Androgen-Responsive Genes and Mechanisms of Hormone Resistance," by Holzbeierlein et al; "TURP and Brachytherapy: Effect on QOL," by Merrick et al.

  • NEUROENDOCRINE DEDIFFERENTIATION OF A PROSTATE ADENOCARCINOMA AFTER HORMONAL TREATMENT - A CASE STUDY. Dema, A.; Taban, S.; Borda, A.; Lazureanu, C.; Muresan, A.; Cornianu, M.; Lazar, E.; Herman, D.; Onet, D.; Popovici, D. // Acta Endocrinologica (1841-0987);Oct-Dec2011, Vol. 7 Issue 4, p535 

    Background. The concept of NE differentiation in prostate carcinoma has two major aspects: prostate tumors with primary NE differentiation and NE differentiation occurred during hormonal therapy for prostate adenocarcinoma, with the extreme case of tumor dedifferentiation into a NE hormone...

  • PROSTATE DISEASES. DIAGNOSTIC MODEL AND CLASSIFICATION METHOD. ANTONYAN, I. M.; UGRYUMOV, M. L.; ZELENSKYI, A. I.; GORIACHA, V. A.; BELOV, V. Y.; NALBANDIAN, T. A.; MOSHEL, F. G. // Belgogrod State University Scientific Bulletin: Medicine, Pharma;2014, Vol. 28 Issue 24, p96 

    This publication contains the description of the joint study of two research groups - the physicians group and the statistics specialists group. The goal of the study was the improvement and stratification of diagnostic process in various prostate diseases. Application of contemporary...

  • Alternative Splicing Programs in Prostate Cancer. Sette, Claudio // International Journal of Cell Biology;2013, p1 

    Prostate cancer (PCa) remains one of the most frequent causes of death for cancer in the male population. Although the initial antiandrogenic therapies are efficacious, PCa often evolves into a hormone-resistant, incurable disease. The genetic and phenotypic heterogeneity of this type of cancer...

  • Cancer de prostata metastatic hormono-refractar. Georgescu, D.; Geavlete, P. // Romanian Journal of Urology;Sep2009, Vol. 8 Issue 3, p52 

    We present the case of a 68 year old man with metastatic prostate cancer, asymptomatic at the moment of the initial diagnostic. After the histopathological confirmation, hormonal therapy based on complete androgen blockade was applied. PSA values first followed a decrease to 2.53 ng/ml, then, at...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics